Apiaceae: A large plant family in the order Apiales, also known as Umbelliferae. Most are aromatic herbs with alternate, feather-divided leaves that are sheathed at the base. The flowers often form a conspicuous flat-topped umbel. Each small individual flower is usually bisexual, with five sepals, five petals, and an enlarged disk at the base of the style. The fruits are ridged and are composed of two parts that split open at maturity.Acorus: A plant genus of the family ACORACEAE, order Arales, subclass Arecidae most notable for Acorus calamus L. root which contains asarone and has been used in TRADITIONAL MEDICINE.Pimenta: A plant genus in the family MYRTACEAE, order Myrtales, subclass Rosidae. It is best known for allspice from the dried berry of Pimenta diocia.Piper nigrum: A plant species in the PIPERACEAE plant family. It is a common spice on foods and is used medicinally to increase gastrointestinal assimilation of other supplements and drugs. Piperine is a key component. Black pepper is picked unripe and heaped for a few days to ferment. White Pepper is the ripe fruit dehulled by maceration in water.Myrtaceae: The myrtle plant family of the order Myrtales. It includes several aromatic medicinal plants such as EUCALYPTUS.Acoraceae: A plant family of the order Arales, subclass Arecidae, class Liliopsida (monocot).Black Pepper: A common spice from fruit of PIPER NIGRUM. Black pepper is picked unripe and heaped for a few days to ferment. White Pepper is the ripe fruit dehulled by maceration in water. Piperine is a key component used medicinally to increase gastrointestinal assimilation of other supplements and drugs.Spices: The dried seeds, bark, root, stems, buds, leaves, or fruit of aromatic plants used to season food.Cuscuta: A plant genus of the family Cuscutaceae. It is a threadlike climbing parasitic plant that is used in DRUGS, CHINESE HERBAL.Asteraceae: A large plant family of the order Asterales, subclass Asteridae, class Magnoliopsida. The family is also known as Compositae. Flower petals are joined near the base and stamens alternate with the corolla lobes. The common name of "daisy" refers to several genera of this family including Aster; CHRYSANTHEMUM; RUDBECKIA; TANACETUM.Periodicals as Topic: A publication issued at stated, more or less regular, intervals.Writing: The act or practice of literary composition, the occupation of writer, or producing or engaging in literary work as a profession.Pharmacies: Facilities for the preparation and dispensing of drugs.Education, Pharmacy: Formal instruction, learning, or training in the preparation, dispensing, and proper utilization of drugs in the field of medicine.Pharmacy: The practice of compounding and dispensing medicinal preparations.Education, Pharmacy, Graduate: Educational programs for pharmacists who have a bachelor's degree or a Doctor of Pharmacy degree entering a specific field of pharmacy. They may lead to an advanced degree.Schools, Pharmacy: Educational institutions for individuals specializing in the field of pharmacy.Publishing: "The business or profession of the commercial production and issuance of literature" (Webster's 3d). It includes the publisher, publication processes, editing and editors. Production may be by conventional printing methods or by electronic publishing.Bibliometrics: The use of statistical methods in the analysis of a body of literature to reveal the historical development of subject fields and patterns of authorship, publication, and use. Formerly called statistical bibliography. (from The ALA Glossary of Library and Information Science, 1983)Journal Impact Factor: A quantitative measure of the frequency on average with which articles in a journal have been cited in a given period of time.Hypertensive Encephalopathy: Brain dysfunction or damage resulting from sustained MALIGNANT HYPERTENSION. When BLOOD PRESSURE exceeds the limits of cerebral autoregulation, cerebral blood flow is impaired (BRAIN ISCHEMIA). Clinical manifestations include HEADACHE; NAUSEA; VOMITING; SEIZURES; altered mental status (in some cases progressing to COMA); PAPILLEDEMA; and RETINAL HEMORRHAGE.Heart Failure: A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION.Angina, Unstable: Precordial pain at rest, which may precede a MYOCARDIAL INFARCTION.Angina Pectoris: The symptom of paroxysmal pain consequent to MYOCARDIAL ISCHEMIA usually of distinctive character, location and radiation. It is thought to be provoked by a transient stressful situation during which the oxygen requirements of the MYOCARDIUM exceed that supplied by the CORONARY CIRCULATION.Renal Circulation: The circulation of the BLOOD through the vessels of the KIDNEY.Myocardial Infarction: NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION).Diabetes Mellitus, Type 2: A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.Treatment Outcome: Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.Diabetes Mellitus: A heterogeneous group of disorders characterized by HYPERGLYCEMIA and GLUCOSE INTOLERANCE.Angioplasty, Balloon, Coronary: Dilation of an occluded coronary artery (or arteries) by means of a balloon catheter to restore myocardial blood supply.Inflammasomes: Multiprotein complexes that mediate the activation of CASPASE-1. Dysregulation of inflammasomes has also been linked to a number of autoinflammatory and autoimmune disorders.Caspase 1: A long pro-domain caspase that has specificity for the precursor form of INTERLEUKIN-1BETA. It plays a role in INFLAMMATION by catalytically converting the inactive forms of CYTOKINES such as interleukin-1beta to their active, secreted form. Caspase 1 is referred as interleukin-1beta converting enzyme and is frequently abbreviated ICE.Hereditary Autoinflammatory Diseases: Hereditary inflammation conditions, characterized by recurrent episodes of systemic inflammation. Common symptoms include recurrent fever, rash, arthritis, fatigue, and secondary AMYLOIDOSIS. Hereditary autoinflammatory diseases are associated with mutations in genes involved in regulation of normal inflammatory process and are not caused by AUTOANTIBODIES, or antigen specific T-LYMPHOCYTES.Interleukin-1beta: An interleukin-1 subtype that is synthesized as an inactive membrane-bound pro-protein. Proteolytic processing of the precursor form by CASPASE 1 results in release of the active form of interleukin-1beta from the membrane.Familial Mediterranean Fever: A group of HEREDITARY AUTOINFLAMMATION DISEASES, characterized by recurrent fever, abdominal pain, headache, rash, PLEURISY; and ARTHRITIS. ORCHITIS; benign MENINGITIS; and AMYLOIDOSIS may also occur. Homozygous or compound heterozygous mutations in marenostrin gene result in autosomal recessive transmission; simple heterozygous, autosomal dominant form of the disease.Carrier Proteins: Transport proteins that carry specific substances in the blood or across cell membranes.Cryopyrin-Associated Periodic Syndromes: A group of rare autosomal dominant diseases, commonly characterized by atypical URTICARIA (hives) with systemic symptoms that develop into end-organ damage. The atypical hives do not involve T-cell or autoantibody. Cryopyrin-associated periodic syndrome includes three previously distinct disorders: Familial cold autoinflammatory syndrome; Muckle-Wells Syndrome; and CINCA Syndrome, that are now considered to represent a disease continuum, all caused by NLRP3 protein mutations.Interleukin-18: A cytokine which resembles IL-1 structurally and IL-12 functionally. It enhances the cytotoxic activity of NK CELLS and CYTOTOXIC T-LYMPHOCYTES, and appears to play a role both as neuroimmunomodulator and in the induction of mucosal immunity.Inflammation: A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.Adipose Tissue: Specialized connective tissue composed of fat cells (ADIPOCYTES). It is the site of stored FATS, usually in the form of TRIGLYCERIDES. In mammals, there are two types of adipose tissue, the WHITE FAT and the BROWN FAT. Their relative distributions vary in different species with most adipose tissue being white.

Angiotensin receptor subtype 1 mediates angiotensin II enhancement of isoproterenol-induced cyclic AMP production in preglomerular microvascular smooth muscle cells. (1/154)

In a previous study, we found that angiotensin (Ang) II enhances beta-adrenoceptor-induced cAMP production in cultured preglomerular microvascular smooth muscle cells (PMVSMCs) obtained from spontaneously hypertensive rats. The purpose of the present investigation was to identify the Ang receptor subtypes that mediate this effect. In our first study, we compared the ability of Ang II, Ang III, Ang (3-8), and Ang (1-7) to increase cAMP production in isoproterenol (1 microM)-treated PMVSMCs. Each peptide was tested at 0.1, 1, 10, 100, and 1000 nM. Both Ang II and Ang III increased intracellular (EC50s, 1 and 11 nM, respectively) and extracellular (EC50s, 2 and 14 nM, respectively) cAMP levels in a concentration-dependent fashion. In contrast, Ang (3-8) and Ang (1-7) did not enhance either intracellular or extracellular cAMP levels at any concentration tested. In our second study, we examined the ability of L 158809 [a selective Ang receptor subtype 1 (AT1) receptor antagonist] to inhibit Ang II (100 nM) and Ang III (100 nM) enhancement of isoproterenol (1 microM)-induced cAMP production in PMVSMCs. L 158809 (10 nM) abolished or nearly abolished (p <.001) Ang II and Ang III enhancement of isoproterenol-induced intracellular and extracellular cAMP levels. In contrast, PD 123319 (300 nM; a selective AT2 receptor antagonist) did not significantly alter Ang II enhancement of isoproterenol-induced intracellular or extracellular cAMP levels. We conclude that AT1 receptors, but not AT2, Ang (3-8), nor Ang (1-7) receptors mediate Ang II and Ang III enhancement of beta-adrenoceptor-induced cAMP production in cultured PMVSMCs.  (+info)

Angiotensin II antagonist prevents electrical remodeling in atrial fibrillation. (2/154)

BACKGROUND: The blockade of angiotensin II (Ang II) formation has protective effects on cardiovascular tissue; however, the role of Ang II in atrial electrical remodeling is unknown. The purpose of this study was to investigate the effects of candesartan and captopril on atrial electrical remodeling. METHODS AND RESULTS: In 24 dogs, the atrial effective refractory period (AERP) was measured before, during, and after rapid atrial pacing. Rapid atrial pacing at 800 bpm was maintained for 180 minutes. The infusion of saline (n=8), candesartan (n=5), captopril (n=6), or Ang II (n=5) was initiated 30 minutes before rapid pacing and continued throughout the study. In the saline group, AERP was significantly shortened during rapid atrial pacing (from 149+/-11 to 132+/-16 ms, P<0.01). There was no significant difference in AERP shortening between the saline group and the Ang II group. However, in the candesartan and captopril groups, shortening of the AERP after rapid pacing was completely inhibited (from 142+/-9 to 147+/-12 ms with candesartan, from 153+/-15 to 153+/-14 ms with captopril, P=NS). Although rate adaptation of the AERP was lost in the saline group, this phenomenon was preserved in the candesartan and captopril groups. CONCLUSIONS: The inhibition of endogenous Ang II prevented AERP shortening during rapid atrial pacing. These results indicate for the first time that Ang II may be involved in the mechanism of atrial electrical remodeling and that the blockade of Ang II may lead to the better therapeutic management of human atrial fibrillation.  (+info)

Angiotensin II inhibits rat arterial KATP channels by inhibiting steady-state protein kinase A activity and activating protein kinase Ce. (3/154)

We used whole-cell patch clamp to investigate steady-state activation of ATP-sensitive K+ channels (KATP) of rat arterial smooth muscle by protein kinase A (PKA) and the pathway by which angiotensin II (Ang II) inhibits these channels. Rp-cAMPS, an inhibitor of PKA, did not affect KATP currents activated by pinacidil when the intracellular solution contained 0.1 mM ATP. However, when ATP was increased to 1.0 mM, inhibition of PKA reduced KATP current, while the phosphatase inhibitor calyculin A caused a small increase in current. Ang II (100 nM) inhibited KATP current activated by the K+ channel opener pinacidil. The degree of inhibition was greater with 1.0 mM than with 0.1 mM intracellular ATP. The effect of Ang II was abolished by the AT1 receptor antagonist losartan. The inhibition of KATP currents by Ang II was abolished by a combination of PKA inhibitor peptide 5-24 (5 microM) and PKC inhibitor peptide 19-27 (100 microM), while either alone caused only partial block of the effect. In the presence of PKA inhibitor peptide, the inhibitory effect of Ang II was unaffected by the PKC inhibitor Go 6976, which is selective for Ca2+-dependent isoforms of PKC, but was abolished by a selective peptide inhibitor of the translocation of the epsilon isoform of PKC. Our results indicate that KATP channels are activated by steady-state phosphorylation by PKA at normal intracellular ATP levels, and that Ang II inhibits the channels both through activation of PKCepsilon and inhibition of PKA.  (+info)

Reactive oxygen species-mediated homologous downregulation of angiotensin II type 1 receptor mRNA by angiotensin II. (4/154)

Recent studies suggest a crucial role of reactive oxygen species (ROS) for the signaling of angiotensin (Ang) II through Ang II type 1 receptor (AT(1)-R). However, the role of ROS in the regulation of AT(1)-R expression has not been explored. In this study, we examined the effect of an antioxidant on the homologous downregulation of AT(1)-R by Ang II. Ang II (10(-6) mol/L) decreased AT(1)-R mRNA with a peak suppression at 6 hours of stimulation in rat aortic vascular smooth muscle cells. Preincubation of vascular smooth muscle cells with N:-acetylcysteine (NAC), a potent antioxidant, almost completely inhibited the Ang II-induced downregulation of AT(1)-R mRNA. The effect of NAC was due to stabilization of the AT(1)-R mRNA that was destabilized by Ang II. The Ang II-induced AT(1)-R mRNA downregulation was also blocked by PD98059, an extracellular signal-regulated protein kinase (ERK) kinase inhibitor. Ang II-induced ERK activation was inhibited by NAC as well as by PD98059. Exogenous H(2)O(2) also suppressed AT(1)-R mRNA. These results suggest that the production of ROS and the activation of ERK are critical for the downregulation of AT(1)-R mRNA. The generation of ROS through stimulation of AT(1)-R not only mediates signaling of Ang II but also may play a crucial role in the adaptation process of AT(1)-R to the sustained stimulation of Ang II.  (+info)

Chronotropic effect of angiotensin II via type 2 receptors in rat brain neurons. (5/154)

Previously, we determined that angiotensin II (Ang II) elicits an Ang II type 2 (AT(2)) receptor-mediated increase of neuronal delayed rectifier K(+) (I(KV)) current in neuronal cultures from newborn rat hypothalamus and brain stem. This requires generation of lipoxygenase (LO) metabolites of arachidonic acid (AA) and activation of serine/threonine phosphatase type 2A (PP-2A). Enhancement of I(KV) results in a decrease in net inward current during the action potential (AP) upstroke as well as shortening of the refractory period, which may lead to alterations in neuronal firing rate. Thus, in the present study, we used whole-cell current clamp recording methods to investigate the AT(2) receptor-mediated effects of Ang II on the firing rate of cultured neurons from the hypothalamus and brain stem. At room temperature, these neurons exhibited spontaneous APs with an amplitude of 77.72 +/- 2.7 mV (n = 20) and they fired at a frequency of 0.8 +/- 0.1 Hz (n = 11). Most cells had a prolonged early after-depolarization that followed an initial fully developed AP. Superfusion of Ang II (100 nM) plus losartan (LOS, 1 microM) to block Ang II type 1 receptors elicited a significant chronotropic effect that was reversed by the AT(2) receptor inhibitor PD 123,319 (1 microM). LOS alone had no effect on any of the parameters measured. The chronotropic effect of Ang II was reversed by the general LO inhibitor 5,8,11,14-eicosatetraynoic acid (10 microM) or by the selective PP-2A inhibitor okadaic acid (1 nM) and was mimicked by the 12-LO metabolite of AA 12-(S)-hydroxy-(5Z, 8Z, 10E, 14Z)-eicosatetraynoic acid. These data indicate that Ang II elicits an AT(2) receptor-mediated increase in neuronal firing rate, an effect that involves generation of LO metabolites of AA and activation of PP-2A.  (+info)

Reversible renal impairment induced by treatment with the angiotensin II receptor antagonist candesartan in a patient with bilateral renal artery stenosis. (6/154)

BACKGROUND: It is well established that ACE-inhibitors should be avoided in patients with renal artery stenosis. In recent years it has also been recommended that caution should be demonstrated when angiotensin II blockers are used in the same type of patients but the evidence is based only on few cases. RESULTS: We describe a case where use of the angiotensin II antagonist candesartan (Atacand) induced renal failure in a patient with bilateral renal artery stenosis. The course of the case is enlighted by results from sequential renography, selective renal vein catheterisation for measurement of renin, and angiographic findings. CONCLUSIONS: In patients with renal artery stenosis the angiotensin II antagonist candesartan should be avoided.  (+info)

Use of positron emission tomography to study AT1 receptor regulation in vivo. (7/154)

Increased sodium intake and enhanced sodium sensitivity are implicated in the pathogenesis of hypertension and in the control of a major regulator of BP, the type 1 angiotensin receptor (AT(1) receptor). An in vivo technique to study changes of renal AT(1) receptors by dietary sodium was developed that uses positron emission tomography (PET). PET revealed that renal cortical AT(1) receptor binding was increased in sodium-loaded compared with sodium-deprived dogs, which correlated with ex vivo estimations of AT(1) receptor numbers. Plasma renin activity, angiotensin II, and aldosterone were inversely related to changes in AT(1) receptor binding. These results demonstrate, for the first time in vivo, that the renal AT(1) receptor is inversely related to the activity of the renin angiotensin system, which may provide a compensatory mechanism to prevent inappropriate fluctuations in arterial BP. The ability to measure AT(1) receptor binding in vivo has potential significance for clinical studies of AT(1) receptors, because PET is a noninvasive imaging technique that is readily applicable in humans.  (+info)

Angiotensin II type 1 and 2 receptors in conduit arteries of normal developing microswine. (8/154)

OBJECTIVE: To identify vascular cells capable of responding to angiotensin II (Ang II) generated in conduit arteries, we examined the Ang II type 1 receptor (AT1R) and Ang II type 2 receptor (AT2R) in the thoracic aorta (TA) and abdominal aorta (AA) and branches in 90-day fetal, 3-week postnatal, and 6-month adult microswine. METHODS AND RESULTS: By autoradiography ((125)I-[Sar(1)Ile(8)]-Ang II with or without AT1R- or AT2R-selective analogues or (125)I-CGP 42112), there were striking rostrocaudal differences in (1) AT2R binding at all ages (prominent in AA wall and branches, sparse in TA wall and branches) and (2) a non-AT2R binding site for CGP 42112 (consistently evident in postnatal TA and branches but absent in AA and branches). Furthermore, patterns of AT2R distribution in infradiaphragmatic arteries were developmentally distinct. In fetal AAs, high-density AT2Rs occupied the inner 60% of the medial-endothelial wall. In postnatal AAs, AT2Rs were sparse in the medial-endothelial wall but prominent in a circumferential smooth muscle alpha-actin-negative cell layer at the medial-adventitial border, occupying approximately 20% to 25% of the AA cross-sectional area. AT1R density in the TA and AA medial-endothelial wall increased with age, whereas AT2R density decreased after birth. CONCLUSIONS: A novel AT2R-positive cell layer confined to postnatal infradiaphragmatic arteries physically links adventitial and medial layers, appears optimally positioned to transduce AT2R-dependent functions of local Ang II, and suggests that adventitial Ang II may elicit regionally distinct vascular responses.  (+info)

*Angiotensin II receptor blocker

Angiotensin II Type 1 Receptor Blockers at the US National Library of Medicine Medical Subject Headings (MeSH). ... Angiotensin II receptor blockers (ARBs), also known as angiotensin II receptor antagonists , AT1 receptor antagonists or ... They block the activation of AT1 receptors, preventing the binding of angiotensin II. Angiotensin II receptor blockers are used ... In a study comparing beta-blocker carvedilol with valsartan, the angiotensin II receptor blocker not only had no deleterious ...

*International nonproprietary name

... olol for beta blockers (e.g. atenolol) -pril for ACE inhibitors (e.g. captopril) -sartan for angiotensin II receptor ... It has been defined as a form to which affixes (of any type) can be attached. Under a different and apparently more common view ... Examples are: -anib for angiogenesis inhibitors (e.g. pazopanib) -anserin for serotonin receptor antagonists, especially 5-HT2 ... a type of anti-inflammatory drugs (e.g. celecoxib) -mab for monoclonal antibodies (e.g. infliximab); see Nomenclature of ...

*Ramipril

... was found to have similar results as telmisartan, an angiotensin II receptor blocker. Angiotensin-converting enzyme ( ... Remuzzi, Giuseppe (April 2006). "Prevention and Treatment of Diabetic Renal Disease in Type 2 Diabetes: The BENEDICT Study". ... thereby lowering the production of angiotensin II and decreasing the breakdown of bradykinin. The decrease in angiotensin II ... Ramipril, sold under the brand name Altace among others, is an angiotensin-converting enzyme (ACE) inhibitor, used to treat ...

*Antihypertensive drug

... angiotensin II receptor antagonists (ARBs), and beta blockers. Which type of medication to use initially for hypertension has ... Angiotensin II receptor antagonists work by antagonizing the activation of angiotensin receptors. azilsartan candesartan ... thiazide-type diuretics, calcium channel blockers, ACE inhibitors, or angiotensin II receptor antagonists. The largest study, ... On the other hand, β-blockers, diuretics, ACE inhibitors, angiotensin receptor blockers, and aldosterone receptor antagonists ...

*Discovery and development of angiotensin receptor blockers

"Clinical Efficacy of a New Angiotensin II Type 1 Receptor Blocker, Pratosartan, in Hypertensive Patients", Hypertension ... The angiotensin receptor blockers (ARBs), also called angiotensin (AT1) receptor antagonists or sartans, are a group of ... "The distribution of angiotensin II type 1 receptors, and the tissue renin-angiotensin systems" (PDF), Molecular Medicine Today ... no matter how high the concentration of Ang II is. The angiotensin receptor blockers can inhibit the receptor in a competitive ...

*Calcium channel blocker

ACE inhibitor Angiotensin II receptor antagonist Nitrate Tfelt-Hansen, P; Tfelt-Hansen, J (2009). "Verapamil for cluster ... N-type, L-type, and T-type voltage-dependent calcium channels are present in the zona glomerulosa of the human adrenal, and ... Several types of calcium channels occur, with a number of classes of blockers, but almost all of them preferentially or ... Ziconotide, a peptide compound derived from the omega-conotoxin, is a selective N-type calcium channel blocker that has potent ...

*Losartan

... competitive angiotensin II receptor type 1 (AT1) antagonist, reducing the end organ responses to angiotensin II. Losartan ... Discovery and development of angiotensin receptor blockers "Losartan Potassium". The American Society of Health-System ... It is in the angiotensin II receptor antagonist family of medication and works by blocking angiotensin II. Losartan was ... As with all angiotensin II type 1 receptor (AT1) antagonists, losartan is used to treatment hypertension. It may also delay ...

*Angiotensin II receptor type 1

... angiotensin-converting enzyme inhibitors and angiotensin receptor blockers are associated with fewer traumatic stress symptoms ... Angiotensin II receptor type 1 or AT1 receptor is the best characterized angiotensin receptor. It has vasopressor effects and ... The angiotensin receptor is activated by the vasoconstricting peptide angiotensin II. The activated receptor in turn couples to ... spliced human type 1 angiotensin II receptor mRNAs are translated at different efficiencies and encode two receptor isoforms". ...

*Telmisartan

... is an angiotensin II receptor blocker that shows high affinity for the angiotensin II receptor type 1 (AT1), with a ... Telmisartan (INN) /tɛlmɪˈsɑːrtən/ is an angiotensin II receptor antagonist (angiotensin receptor blocker, ARB) used in the ... "Angiotensin II type 1 receptor blocker telmisartan induces apoptosis and autophagy in adult T‐cell leukemia cells". FEBS open ... "Angiotensin II receptor blocker telmisartan enhances running endurance of skeletal muscle through activation of the PPAR-δ/AMPK ...

*Renin-angiotensin system

Angiotensin II receptor antagonists, also known as angiotensin receptor blockers, can be used to prevent angiotensin II from ... Emphasis on Blockade of the Angiotensin II Type-1 Receptor". Medscape Cardiology. 9 (2). Paul M, Poyan Mehr A, Kreutz R (July ... The decapeptide is known as angiotensin I. Angiotensin I is then converted to an octapeptide, angiotensin II by angiotensin- ... Angiotensin II is the major bioactive product of the renin-angiotensin system, binding to receptors on intraglomerular ...

*Glossary of diabetes

Receptors Regular insulin A type of insulin that is fast acting. Renal Related to the kidneys. Renal threshold When the blood ... Insulin is a hormone as are glucagon, adrenaline, and angiotensin II. Human insulin Man-made insulins that is identical to the ... ARB Angiotensisn Receptor Blocker. An agent which interferes with the renin (kidney-lung-heart blood pressure control) cycle. ... Most Type II diabetics are without clinically obvious symptoms for some time (often years) before they are diagnosed as ...

*Angioedema

... such as an angiotensin II receptor blocker (ARB) which has a similar mechanism but does not affect bradykinin. However, this is ... The three types of hereditary angioedema are: Type I - decreased levels of C1INH (85%); Type II - normal levels, but decreased ... type I HAE) or dysfunctional forms of the same protein (type II HAE). Type III HAE has been linked with mutations in the F12 ... of angioedema associated with the use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers". Annals of ...

*Antagonism (chemistry)

Kalaitzidis, R; Bakris, G. L. (2009). "Effects of angiotensin II receptor blockers on diabetic nephropathy". Journal of ... An example of this is the interleukin-1 receptor antagonist. The opposite of antagonism is synergy. It is a negative type of ... For example, not only do angiotensin receptor blockers, and angiotensin-converting enzyme (ACE) inhibitors work to lower blood ... For instance, a receptor antagonist is an agent that reduces the response that a ligand produces when the receptor antagonist ...

*Valsartan

It is an angiotensin II receptor antagonist (commonly called an ARB, or angiotensin receptor blocker), that is selective for ... The drug binds to angiotensin type I receptors (AT1), working as an antagonist. This mechanism of action is different than that ... Angiotensin II receptor antagonist Discovery and development of angiotensin receptor blockers Valsartan/hydrochlorothiazide ... As valsartan acts at the receptor, it can provide more complete angiotensin II antagonism since angiotensin II is generated by ...

*Heart failure with preserved ejection fraction

Angiotensin II receptor blocker treatment shows an improvement in diastolic dysfunction and hypertension that is comparable to ... Senile systemic amyloidosis, resulting from accumulation of aggregated wild-type transthyretin as part of the degenerative ... Currently treatment with ACE inhibitors, calcium channel blockers, beta blockers, and angiotensin receptor blockers are ... Effect of angiotensin receptor blockade and antihypertensive drugs on diastolic function in patients with hypertension and ...

*Angiotensin (1-7)

In addition, it has been demonstrated that ACE inhibitors decrease Ang (1-7) expression whereas Angiotensin II receptor type 1 ... This pharmacological interplay between Ang II and AT1 blockers favors Ang (1-7) formation. Santos, R. A. S.; Ferreira, A. J.; ... Action of the ACE on Angiotensin 1-9. Action of the neprilysinon Angiotensin 1-9. Action of the ACE2 on Angiotensin II. The ... Zisman, L. S. (7 October 2003). "Angiotensin-(1-7) Formation in the Intact Human Heart: In Vivo Dependence on Angiotensin II as ...

*Alpha-7 nicotinic receptor

... is prevented through angiotensin II activation of a tyrosine phosphatase". J. Pharmacol. Exp. Ther. 309 (1): 16-27. doi:10.1124 ... The alpha-7 nicotinic receptor, also known as the α7 receptor, is a type of nicotinic acetylcholine receptor implicated in long ... α7 subtype preferring blocker α3β2-Nicotinic receptor α3β4-Nicotinic receptor α4β2-Nicotinic receptor RIC3, a chaperone protein ... Although ethanol inhibition of the α7-receptor is likely to involve the N-terminal region of the receptor, the site of action ...

*Sacubitril/valsartan

Valsartan blocks the angiotensin II receptor type 1 (AT1). This receptor is found on both vascular smooth muscle cells, and on ... Sacubitril/valsartan can be used instead of an ACE inhibitor or an angiotensin receptor blocker in people with heart failure ... Changing 100 people from an ACE inhibitor or angiotensin II receptor antagonist to sacubitril/valsartan for 2.3 years would ... It consists of the neprilysin inhibitor, sacubitril and the angiotensin receptor blocker, valsartan, in a 1:1 mixture by ...

*List of MeSH codes (D16)

... angiotensin ii type 1 receptor blockers MeSH D27.505.519.170 --- antacids MeSH D27.505.519.186 --- antimetabolites MeSH D27.505 ... calcium channel blockers MeSH D27.505.519.562.374 --- ionophores MeSH D27.505.519.562.500 --- potassium channel blockers MeSH ... sodium channel blockers MeSH D27.505.954.411.793 --- vasoconstrictor agents MeSH D27.505.954.411.793.205 --- calcium channel ... angiotensin-converting enzyme inhibitors MeSH D27.505.519.389.745.325 --- cysteine proteinase inhibitors MeSH D27.505.519.389. ...

*Proteinuria

... or angiotensin receptor blocker (ARB) may further reduce protein loss. Caution must be used if these agents are added to ACE ... Chou JY, Matern D, Mansfield BC, Chen YT (2002). "Type 1 Glycogen Storage Diseases: Disorders of the Glucose-6-Phosphatase ... the cause of the underlying proteinuria should be separated into two categories: diabetic proteinuria versus the field. With ... "Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximum angiotensin-converting enzyme inhibition ...

*Forasartan

... is a nonpeptide angiotensin II receptor antagonist (ARB, AT1 receptor blocker). Forasartan is indicated for the treatment of ... Naik, P; Murumkar P (2010). "Angiotensin II receptor type 1 (AT1) selective nonpeptidic antagonists-A perspective". Bioorganic ... "an Orally Active Angiotensin II-Receptor Antagonist: Inhibition of Blood Pressure Response to Angiotensin II Challenges and ... Angiotensin II binds to AT1 receptors, increases contraction of vascular smooth muscle, and stimulates aldosterone resulting in ...

*Fostamatinib

... have been treated with an Angiotensin Converting Enzyme inhibitor (ACEi) and/or an Angiotensin II Receptor Blocker (ARB) for at ... mixed type AIHA, or paroxysmal cold hemoglobinuria. Fostamatinib as a treatment for IgA nephropathy (IgAN) is in Phase II ... A phase II study of rheumatoid arthritis patients failing to respond to a biologic agent showed little efficacy as compared to ... Approval for treatment of autoimmune hemolytic anemia (AIHA) is in Stage 1 of Phase II trials. This study is a Phase 2, multi- ...

*Scleroderma

... alpha blockers, serotonin receptor antagonists, angiotensin II receptor inhibitors, statins, local nitrates or iloprost Digital ... Mycosis fungoides, a type of cutaneous T cell lymphoma, a rare cancer that causes rashes all over the body. Nephrogenic ... disease with antacids or prokinetics Kidney crises with angiotensin converting enzyme inhibitors and angiotensin II receptor ... Choctaw Native Americans are more likely than Americans of European descent to develop the type of scleroderma that affects ...

*Thiazide

In this context, "thiazide" is taken to refer to a drug which acts at a "thiazide receptor", which is believed to be a sodium- ... Thiazide (/ˈθaɪəzaɪd/) is a type of molecule and a class of diuretics often used to treat hypertension (high blood pressure) ... Thiazides have also been replaced by angiotensin converting enzyme (ACE) inhibitors in Australia due to their propensity to ... Hypokalemia - Thiazide diuretics reduces potassium concentration in blood through two indirect mechanisms: inhibition of sodium ...

*Tachycardia-induced cardiomyopathy

... or angiotensin II receptor blockers (ARBs) along with symptomatic management with diuretics. Beta-blockers and ACE inhibitors ... In patients with TIC due to other types of SVT, RF catheter ablation is recommended as a first-line treatment. In patients with ... The treatment of heart failure commonly involves neurohormonal blockade with beta-blockers and angiotensin convertase ... The types of SVT associated with TIC include atrial fibrillation, atrial flutter, incessant atrial tachycardia, permanent ...

*Pharmaceutical industry

... beta blockers (ICI Pharmaceuticals, 1964) ACE inhibitors, and angiotensin receptor blockers. ACE inhibitors reduce the risk of ... Phase II can include pharmacokinetics and dosing in patients, and Phase III is a very large study of efficacy in the intended ... By the 1890s, the profound effect of adrenal extracts on many different tissue types had been discovered, setting off a search ... US congress signed into law a bill which requires phase II and phase III clinical trials to be registered by the sponsor on the ...
The nucleus, being the largest sub-cellular compartment, varies in diameter from 10 to 20 micrometres. It is surrounded by a double membrane forming the nuclear envelope, about 30 nm wide. This selectively allows molecules to enter and leave the nucleus, and separates chemical reactions taking place in cytoplasm from reactions happening within the nucleus. The outer membrane has ribosomes. The inner and outer membrane fuse at regular spaces, forming nuclear pores. Similar to the cytoplasm of a cell, the nucleus contains nucleoplasm - a highly viscous solid containing the chromosomes and nucleoli. Chromosones contain information encoded in DNA attached to proteins called histones and are usually arranged in to a dense network called chromatin. Nucleoli are granular structures which make ribonucleic DNA (rDNA) and assemble it with proteins ...
I can deal with synced periods among a few friends, but the more research produced about the effect brothers and fathers have on girls, the less I want to
Angiotensin II Type 1 Receptor兔多克隆抗体(ab84289)可与人样本反应并经WB实验严格验证,被1篇文献引用。所有产品均提供质保服务,中国75%以上现货。
Buy our Angiotensin II Type 1 Receptor peptide. Ab176148 is a blocking peptide for ab124505 and has been validated in BL. Abcam provides free protocols, tips…
Buy AT1R elisa kit, Mouse Angiotensin II type 1 receptor (AT1R) ELISA Kit-AAF66063.1 (MBS268629) product datasheet at MyBioSource, ELISA Kits
Receptor Blockers - MedHelps Receptor Blockers Center for Information, Symptoms, Resources, Treatments and Tools for Receptor Blockers. Find Receptor Blockers information, treatments for Receptor Blockers and Receptor Blockers symptoms.
These studies demonstrate that RI Ang II, an AT2R ligand, does not induce a natriuresis in the presence of systemic AT1R blockade. However, a natriuretic response to Ang II, mediated by the AT2R, is unmasked by the intrarenal addition of PC-18, an APN inhibitor. Because the metabolism of Ang III to Ang IV by APN is inhibited by PC-18, these data suggest that Ang III is a significant mediator of Ang II-induced natriuresis. This conclusion is further supported by the ability of APA inhibition to abolish the natriuretic response to Ang II+PC-18.. Previous studies from our laboratory have shown that in the presence of AT1R blockade, RI Ang III infusion results in natriuresis that is abolished by concomitant PD infusion, implicating the renal AT2R in the response.21 Furthermore, addition of RI PC-18 to Ang III infusion causes a 1.8- to 2.8-fold increase in Na+ excretion compared with RI Ang III infusion alone.22 These findings prompted the present set of investigations to determine whether renal ...
A randomized controlled study to compare the effects of angiotensin II type 1 receptor blockers (telmisartan vs candesartan vs valsartan) on the markers of cardiovascular risk in hypertensive patients with type 2 diabetes mellitus ...
We investigated in mice whether atherosclerosis exacerbates the development of post-ischemic heart failure and alters the beneficial effects of long-term angiotensin II type 1 receptor blockade in this model. ApoE-deficient (ApoE(-/-)) and C57BL/6J (
Thank you for your interest in spreading the word on Hypertension.. NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address. ...
The table below shows the top 100 pain related interactions that have been reported for angiotensin type II receptor activity. They are ordered first by their pain relevance and then by number of times they were reported for angiotensin type II receptor activity. Please click on the INT link to display more detailed information on each interaction. ...

The Impact of ACE Inhibitors or Angiotensin II Type 1 Receptor Blockers on the Development of New-Onset Type 2 Diabetes -...The Impact of ACE Inhibitors or Angiotensin II Type 1 Receptor Blockers on the Development of New-Onset Type 2 Diabetes -...

The Impact of ACE Inhibitors or Angiotensin II Type 1 Receptor Blockers on the Development of New-Onset Type 2 Diabetes. 7 ... The Impact of ACE Inhibitors or Angiotensin II Type 1 Receptor Blockers on the Development of New-Onset Type 2 Diabetes. ... or angiotensin receptor blocker (ARB) may experience a decreased incidence of new-onset type 2 diabetes. ... two trials), or heart failure (two trials), reductions in new-onset type 2 diabetes were maintained (0.79 [0.72-0.85], 0.76 [ ...
more infohttp://www.thaiendocrine.org/en/2017/08/07/the-impact-of-ace-inhibitors-or-angiotensin-ii-type-1-receptor-blockers-on-the-development-of-new-onset-type-2-diabetes/

Effect of candesartan cilexetil on carotid intima-media thickness in hypertensive type 2 diabetic patients . MITEC study :...Effect of candesartan cilexetil on carotid intima-media thickness in hypertensive type 2 diabetic patients . MITEC study :...

... in hypertensive type 2 diabetic patients. The study design, the baseline characteristics, and the determinants of carotid IMT ... The renal protective effects of angiotensin II receptor blockers in type 2 diabetes mellitus.. *James D Coyle, Stephanie F ... Comparison of the effects of antihypertensive treatment with angiotensin II blockade and beta-blockade on carotid wall ... Effect of candesartan cilexetil on carotid intima-media thickness in hypertensive type 2 diabetic patients . MITEC study : ...
more infohttps://www.semanticscholar.org/paper/Effect-of-candesartan-cilexetil-on-carotid-in-type-Valensi-Baguet/482b800bc2b02a58a4b9695a45a6e31e3fd0db7b

Irbesartan is projected to be cost and life saving in a Spanish setting for treatment of patients with type 2 diabetes,...Irbesartan is projected to be cost and life saving in a Spanish setting for treatment of patients with type 2 diabetes,...

Two strategies were compared: (1) irbesartan versus (2) standard hypertension care with comparable blood pressure control; both ... CONCLUSION Treating patients with hypertension, microalbuminuria, and type 2 diabetes with irbesartan was projected to reduce ... type 2 diabetes, and microalbuminuria was adapted to a Spanish setting. ... 2%, save 11,082 +/- 2,996 euro, and add 1.40 +/- 0.27 life years per treated patient. The superiority of irbesartan over ...
more infohttps://www.semanticscholar.org/paper/Irbesartan-is-projected-to-be-cost-and-life-saving-Palmer-Annemans/7807fa5b764c6b90346507e6dc2cc0b427a30029

A Category Names List - Drug Information Portal - U.S. National Library of MedicineA Category Names List - Drug Information Portal - U.S. National Library of Medicine

Angiotensin II Type 1 Receptor Blockers (21) • Agents that antagonize ANGIOTENSIN II TYPE 1 RECEPTOR. Included are ANGIOTENSIN ... Angiotensin II Type 2 Receptor Blockers (2) • Agents that antagonize the ANGIOTENSIN II TYPE 2 RECEPTOR. MeSH ... Angiotensin Receptor Antagonists (25). Angiotensin-Converting Enzyme Inhibitors (46) • A class of drugs whose main indications ... Adenosine A2A Receptor Agonists (0) see Adenosine A2 Receptor Agonists. Adenosine A2A Receptor Antagonists (0) see Adenosine A2 ...
more infohttps://druginfo.nlm.nih.gov/drugportal/drug/categories

A Category Names List - Drug Information Portal - U.S. National Library of MedicineA Category Names List - Drug Information Portal - U.S. National Library of Medicine

Angiotensin II Type 1 Receptor Blockers (21) • Agents that antagonize ANGIOTENSIN II TYPE 1 RECEPTOR. Included are ANGIOTENSIN ... Angiotensin II Type 2 Receptor Blockers (2) • Agents that antagonize the ANGIOTENSIN II TYPE 2 RECEPTOR. MeSH ... Angiotensin Receptor Antagonists (25). Angiotensin-Converting Enzyme Inhibitors (46) • A class of drugs whose main indications ... Adenosine A2A Receptor Agonists (0) see Adenosine A2 Receptor Agonists. Adenosine A2A Receptor Antagonists (0) see Adenosine A2 ...
more infohttps://druginfo.nlm.nih.gov/drugportal/jsp/drugportal/drugNamesAndCategories.jsp

ChemIDplus - 130663-39-7 - YSTVFDAKLDMYCR-UHFFFAOYSA-N - PD 123319 - Similar structures search, synonyms, formulas, resource...ChemIDplus - 130663-39-7 - YSTVFDAKLDMYCR-UHFFFAOYSA-N - PD 123319 - Similar structures search, synonyms, formulas, resource...

Angiotensin receptor type 2 receptor inhibitor resulting in vasoconstriction.. Classification Codes. *. Angiotensin II Type 2 ...
more infohttps://chem.nlm.nih.gov/chemidplus/rn/130663-39-7

The Risk for Type B Aortic Dissection in Marfan Syndrome | Journal Scan - American College of CardiologyThe Risk for Type B Aortic Dissection in Marfan Syndrome | Journal Scan - American College of Cardiology

The use of angiotensin-II receptor blockers was associated with fewer type B aortic dissections (HR, 0.3; 95% CI, 0.1-0.9; p = ... Finally, this study suggests that the use of angiotension-II receptor blockers may be associated with fewer type B dissections ... Keywords: Marfan Syndrome, Aneurysm, Dissecting, Angiotensin II Type 2 Receptor Blockers, Aorta, Risk, Magnetic Resonance ... While 37% of patients had prophylactic ascending aortic repair during follow-up, only two patients (0.3%) experienced type A ...
more infohttp://www.acc.org/latest-in-cardiology/journal-scans/2015/01/22/15/16/the-risk-for-type-b-aortic-dissection-in-marfan-syndrome

coyle.1@osu.edu | College of Pharmacy[email protected] | College of Pharmacy

The renal protective effects of angiotensin II receptor blockers in type 2 diabetes mellitus. The Annals of pharmacotherapy. ... 1992 Aug;20(2):197-205. *Carnes, CA; Coyle, JD. Evaluation of very rapid emit Qst methods for measuring serum procainamide and ...
more infohttp://pharmacy.osu.edu/faculty-staff/users/coyle1

Drugs: cardiovascular system | CMAJDrugs: cardiovascular system | CMAJ

... effectiveness of angiotensin-converting-enzyme inhibitors and angiotensin II receptor blockers in patients with type 2 diabetes ... Cases: Two cases of cardiac glycoside poisoning from accidental foxglove ingestion Renée M. Janssen, Mattias Berg and Daniel H ...
more infohttp://www.cmaj.ca/drugs_cardiovascular_system

IJCS - SumárioIJCS - Sumário

Are angiotensin II receptor blockers linked to cancer? Os bloqueadores dos receptores de angiotensina II estão relacionados à ... Although step tests are used frequently for healthy people and patients with lung diseases, this type of test is still quite ... The association between angiotensin receptor blockers (ARBs) and cancer has shown conflicting results in clinical studies and ... The protocols used were the two-minute step test and the Master two-step test. Four studies compared step test performance to ...
more infohttp://onlineijcs.com/sumario/31

Treatment of painful diabetic neuropathy<...Treatment of painful diabetic neuropathy<...

N-type calcium channel blockers, NGF antibodies and angiotensin II type 2 receptor antagonists. ... N-type calcium channel blockers, NGF antibodies and angiotensin II type 2 receptor antagonists.", ... N-type calcium channel blockers, NGF antibodies and angiotensin II type 2 receptor antagonists. ... N-type calcium channel blockers, NGF antibodies and angiotensin II type 2 receptor antagonists. ...
more infohttps://qfrd.pure.elsevier.com/en/publications/treatment-of-painful-diabetic-neuropathy

Maffioli, P.<...Maffioli, P.<...

... clinical trial of canrenone vs hydrochlorothiazide in addition to angiotensin II receptor blockers in hypertensive type 2 ... 2, p. 123-129 7 p.. Research output: Contribution to journal › Review article ...
more infohttps://moh-it.pure.elsevier.com/en/persons/pamela-maffioli

Angiotensin Type 2 Receptor | Springer for Research & DevelopmentAngiotensin Type 2 Receptor | Springer for Research & Development

... the angiotensin II type 1 receptor (AT1R), and is similarly... ... II receptor type 2 The angiotensin II type 2 receptor (AT2R) ... the angiotensin II type 1 receptor (AT1R), and is similarly a part of the renin-angiotensin II system (RAS). The RAS is best ... Protective role of angiotensin II type 2 receptor signaling in a mouse model of pancreatic fibrosis. Am J Physiol Gastrointest ... The angiotensin II type 2 receptor (AT2R) shares a high degree of homology with its well-known sister gene, ...
more infohttps://rd.springer.com/referenceworkentry/10.1007/978-3-319-67199-4_451

Ehlers-Danlos Syndrome, Vascular Type disease: Malacards - Research Articles, Drugs, Genes, Clinical TrialsEhlers-Danlos Syndrome, Vascular Type disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

Angiotensin II Type 1 Receptor Blockers. Phase 3. 20. protease inhibitors. Phase 3. ... Angiotensin II Receptor Blockade in Vascular Ehlers Danlos Syndrome (ARCADE). Recruiting. NCT02597361 Phase 3. Irbesartan; ... Isoleucyl(5)-angiotensin II. N-(1-(N-(N-(N-(N-(N(2)-L-a-Aspartyl-L-arginyl)-L-valyl)-L-tyrosyl)-L-isoleucyl)-L-histidyl)-L- ... MalaCards integrated aliases for Ehlers-Danlos Syndrome, Vascular Type:. Name: Ehlers-Danlos Syndrome, Vascular Type 57 24 53 ...
more infohttps://www.malacards.org/card/ehlers_danlos_syndrome_vascular_type

Randomized trial of an increased dose of calcium channel blocker or angiotensin II type 1 receptor blocker as an add-on...Randomized trial of an increased dose of calcium channel blocker or angiotensin II type 1 receptor blocker as an add-on...

... a lack of data on how to treat hypertensive patients with diabetes when treatment with medium doses of calcium channel blocker ... and angiotensin II type 1 receptor blocker (ARB) is... ... Angiotensin II type 1 receptor blocker Calcium channel blocker ... Randomized trial of an increased dose of calcium channel blocker or angiotensin II type 1 receptor blocker as an add-on ... patients with diabetes when treatment with medium doses of calcium channel blocker and angiotensin II type 1 receptor blocker ( ...
more infohttps://link.springer.com/article/10.1007%2Fs00380-018-1286-2

BMC Nephrology | Guidelines and policyBMC Nephrology | Guidelines and policy

Economic evaluations of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in type 2 diabetic ... Content type: Research article. Routine serum creatinine measurements: how well do we perform? The first aim of the study was ... Content type: Review. Fabry nephropathy: a review - how can we optimize the management of Fabry nephropathy? Fabry disease is a ... Content type: Correspondence. The Pioneers of Nephrology - Professor Gabriel Richet: "I will maintain" Gabriel Richet was one ...
more infohttps://bmcnephrol.biomedcentral.com/articles/sections/guidelines-and-policy

Long-term prevention of diabetic nephropathy: an audit | SpringerLinkLong-term prevention of diabetic nephropathy: an audit | SpringerLink

Aims/hypothesis In type 1 diabetic patients with microalbuminuria not receiving antihypertensive treatment, an increase in ... Angiotensin II receptor blockers (ARBs) have been shown to have a similar effect in type 2 diabetic patients with ... or angiotensin II receptor blocker (ARB) in microalbuminuric type 1 diabetic patients on progression of microalbuminuria and ... ACE inhibitors Angiotensin II receptor blockers Audit Diabetic nephropathy Microalbuminuria Prevention RAAS blockade Renin- ...
more infohttps://link.springer.com/article/10.1007%2Fs00125-008-0990-3

Could Big Lifestyle Changes Be Key to Managing Type 2 Diabetes? - Drugs.com MedNewsCould Big Lifestyle Changes Be Key to Managing Type 2 Diabetes? - Drugs.com MedNews

When it comes to type 2 diabetes management, a new study finds that more is definitely better for lowering blood sugar levels. ... FDA Updates on Angiotensin II Receptor Blocker (ARB) Recalls. Investigation ongoing - This page to be updated as more ... Motegrity Motegrity (prucalopride) is a selective serotonin type 4 (5‑HT4) receptor agonist for the treatment of c... ... A1C is a blood test that estimates average blood sugar levels over two to three months. An A1C of 6.5 percent or higher ...
more infohttps://www.drugs.com/news/could-big-lifestyle-changes-key-managing-type-2-diabetes-66674.html

A Single β-Amino Acid Substitution to Angiotensin II Confers AT
            2
            Receptor Selectivity and Vascular...A Single β-Amino Acid Substitution to Angiotensin II Confers AT 2 Receptor Selectivity and Vascular...

Angiotensin II (MeSH) * Angiotensin II Type 2 Receptor Blockers (MeSH) * Animals (MeSH) ... Ang II and Ang II fully displaced [(125)I]-Ang II from AT(1)R. In contrast, β-substitutions at each position of Ang II ... R ligands were designed by substituting individual β-amino acid in the sequence of the native ligand angiotensin II (Ang II). ... A Single β-Amino Acid Substitution to Angiotensin II Confers AT 2 Receptor Selectivity and Vascular Function Academic Article * ...
more infohttps://scholars.latrobe.edu.au/display/publication534976

In This Issue of Diabetes | DiabetesIn This Issue of Diabetes | Diabetes

Although angiotensin II receptor blockers are commonly prescribed for type 2 diabetic patients with azotemia, whether they can ... A unique feature of the study is that the two groups were matched for both amount and rate of weight loss, a methodological ... Losartan May Slow the Progression of Some Features of Kidney Disease in American Indians With Type 2 Diabetes. In this issue of ... p. 3224) report results from a randomized clinical trial of losartan treatment and show that among American Indians with type 2 ...
more infohttp://diabetes.diabetesjournals.org/content/62/9/2995.full

Safety and feasibility of achieving lower systolic blood pressure goals in persons with type 2 diabetes: the SANDS trial.Safety and feasibility of achieving lower systolic blood pressure goals in persons with type 2 diabetes: the SANDS trial.

... was a randomized open-label clinical trial in type 2 diabetics designed to examine the effects of intensive reduction of blood ... Angiotensin II Type 1 Receptor Blockers / adverse effects, therapeutic use. Angiotensin-Converting Enzyme Inhibitors / adverse ... 0/Angiotensin II Type 1 Receptor Blockers; 0/Angiotensin-Converting Enzyme Inhibitors; 0/Antihypertensive Agents; 0/Cholesterol ... Diabetes Mellitus, Type 2 / blood, complications*, physiopathology. Drug Tolerance. Female. Humans. Hypertension / drug therapy ...
more infohttp://www.biomedsearch.com/nih/Safety-feasibility-achieving-lower-systolic/19817934.html

Telmisartan, an angiotensin II receptor blocker, attenuates Prevotella intermedia lipopolysaccharide-induced production of...Telmisartan, an angiotensin II receptor blocker, attenuates Prevotella intermedia lipopolysaccharide-induced production of...

... has an anti-inflammatory property in addition to being an angiotensin II type 1 receptor antag... ... Telmisartan (TEL), an angiotensin II type I receptor blocker and PPARγ partial agonist, has been used for to treat hypertension ... Telmisartan (TLM), a highly selective angiotensin II type 1 receptor blocker (ARB) and partial PPAR-γ agonist, has versatile ... An ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKER that is used to manage HYPERTENSION. ...
more infohttps://www.bioportfolio.com/resources/pmarticle/2430651/Telmisartan-an-angiotensin-II-receptor-blocker-attenuates-Prevotella-intermedia-lipopolysaccharide-induced-production.html

Using spatial analysis to demonstrate the heterogeneity of the cardiovascular drug-prescribing pattern in Taiwan | BMC Public...Using spatial analysis to demonstrate the heterogeneity of the cardiovascular drug-prescribing pattern in Taiwan | BMC Public...

LISA provides information on types of spatial association at the local level. LISA statistics can also be used to identify ... Use of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers in patients with type 2 diabetic chronic ... Lin TL, Yang YHK, Tang CH, Wu HM, Cheng HW: Impact of introduction of angiotensin II antagonist on the anti hypertensive ... b. Group A, agents acting on the rennin-angiotensin system; Group B, beta blocking agents; Group C, calcium channel blockers; ...
more infohttps://bmcpublichealth.biomedcentral.com/articles/10.1186/1471-2458-11-380

Zofenil | Medicines.ieZofenil | Medicines.ie

... of adding aliskiren to a standard therapy of an ACE-inhibitor or an angiotensin II receptor blocker in patients with type 2 ... Details of two studies added with details about the use of combination of an ACE-inhibitor with an angiotensin II receptor ... angiotensin II receptor blockers or aliskiren is not recommended, ... Change to section 2 - what you need to know - contraindications * Change to section 2 - what you need to know - warnings and ...
more infohttps://www.medicines.ie/medicines/zofenil-34359/company-info/page-1/per-page-25

JCI Insight -
Inhibition of the methyltranferase EZH2 improves aortic performance in experimental thoracic aortic aneurysmJCI Insight - Inhibition of the methyltranferase EZH2 improves aortic performance in experimental thoracic aortic aneurysm

... some with anti-TGF-β activity such as angiotensin II receptor blockers (ARBs) or angiotensin-converting enzyme inhibitors (ACE ... This type of mechanism is more relevant to the ascending aortic aneurysm, which has a unique clinical profile even in the ... Angiotensin II-dependent TGF-β signaling contributes to Loeys-Dietz syndrome vascular pathogenesis. J Clin Invest. 2014;124(1): ... TGF-beta activity protects against inflammatory aortic aneurysm progression and complications in angiotensin II-infused mice. J ...
more infohttps://insight.jci.org/articles/view/97493
  • Prior prophylactic aortic surgery or a dilated proximal descending aorta is associated with increased risk of type B dissection in these patients. (acc.org)
  • This cohort experienced a much larger rate of type B aortic dissection (1.5% per year), with both prior aortic surgery and the presence of a dilated proximal descending aorta independently associated with increased risk of these events. (acc.org)
  • Ehlers-Danlos Syndrome, Vascular Type, also known as eds iv , is related to ehlers-danlos syndrome and aortic aneurysm , and has symptoms including hemoptysis An important gene associated with Ehlers-Danlos Syndrome, Vascular Type is COL3A1 (Collagen Type III Alpha 1 Chain), and among its related pathways/superpathways are Integrin Pathway and Phospholipase-C Pathway . (malacards.org)
  • 57 The vascular type of Ehlers-Danlos syndrome is characterized by the joint and dermal manifestations as in other forms of the syndrome but also by proneness to spontaneous rupture of bowel and large arteries. (malacards.org)
  • 75 Ehlers-Danlos syndrome, vascular type: A severe form of Ehlers-Danlos syndrome, a group of connective tissue disorders characterized by skin hyperextensibility, articular hypermobility, and tissue fragility. (malacards.org)
  • Relative ATR selectivity and functional vascular assays (in vitro AT(2)R-mediated vasorelaxation and in vivo vasodepressor action) were determined. (edu.au)
  • The signalling of AT2 and the influence on the collagen metabolism of AT2 receptor in adult rat cardiac fibroblasts. (springer.com)
  • In a study comparing beta-blocker carvedilol with valsartan, the angiotensin II receptor blocker not only had no deleterious effect on sexual function, but actually improved it. (wikipedia.org)
  • Each drug's INN is unique but may contain a word stem that is shared with other drugs of the same class, for example the beta blocker drugs propranolol and atenolol share the -olol suffix, and the benzodiazepine drugs lorazepam and diazepam share the -azepam suffix. (wikipedia.org)
  • OBJECTIVE -Angiotensin II has been shown to increase hepatic glucose production and decrease insulin sensitivity. (thaiendocrine.org)
  • The investigators collected data on numerous aspects of insulin sensitivity and β-cell function to determine how these diverse measures responded to the two interventions. (diabetesjournals.org)
  • Very low-calorie diet mimics the early beneficial effect of Roux-en-Y gastric bypass on insulin sensitivity and β-cell function in type 2 diabetic patients. (diabetesjournals.org)
  • Media Intima Thickness Evaluation of Candesartan (MITEC), a multicentre, randomised, double-blind, parallel-group study assessed the effect of candesartan cilexetil (CC) versus amlodipine (AML) administered during three years, on carotid intima-media thickness (IMT) in hypertensive type 2 diabetic patients. (semanticscholar.org)
  • What are the clinical predictors of type B aortic dissection in patients with Marfan syndrome? (acc.org)
  • During follow-up, type A and type B aortic dissections occurred in 2 and 54 patients, respectively. (acc.org)
  • While 37% of patients had prophylactic ascending aortic repair during follow-up, only two patients (0.3%) experienced type A aortic dissection, which suggests that current clinical practice may be effective. (acc.org)
  • While these variables may be helpful to identify those at greater risk, each of these variables was present in about half of patients with subsequent type B dissection, and many of these patients had neither or only one of these risk factors. (acc.org)
  • Microalbuminuria has previously been demonstrated to precede and predict the development of diabetic nephropathy in type 1 diabetic patients. (springer.com)
  • A total of 227 type 1 diabetic patients with persistent microalbuminuria were included for follow-up. (springer.com)
  • In competition binding experiments using either AT(1)R- or AT(2)R- transfected HEK-293 cells, only β-Asp(1)-Ang II and Ang II fully displaced [(125)I]-Ang II from AT(1)R. In contrast, β-substitutions at each position of Ang II exhibited AT(2)R affinity, with β-Tyr(4)-Ang II and β-Ile(5)-Ang II exhibiting ≈ 1000-fold AT(2)R selectivity. (edu.au)
  • The study examined variables associated with type B aortic dissection or a combined endpoint of type B aortic dissection, distal aortic surgery, or death. (acc.org)
  • A unique feature of the study is that the two groups were matched for both amount and rate of weight loss, a methodological feature that has been absent in previous attempts to explore RYGB-associated weight loss. (diabetesjournals.org)
  • On multivariable analysis, aortic distensibility and the presence of an aortic hump were not associated with type B aortic dissection. (acc.org)
  • The authors concluded that type B aortic dissection is not uncommon in those with Marfan syndrome. (acc.org)
  • LDL cholesterol (the bad kind) and triglycerides (another type of bad blood fat) were reduced more in the intensive group than in the standard group. (drugs.com)